Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on July 19, 2017, by Dare Bioscience, Inc., a Delaware corporation previously known as Cerulean Pharma Inc. The filing reports the closing of the "Dare Transaction," a stock purchase agreement entered into on March 19, 2017, with Dare Bioscience Operations, Inc. (formerly Dare Bioscience, Inc.). The report also confirms the completion of the Company's reverse stock split and name change.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate structural changes rather than periodic financial performance data.
Material Changes
- Transaction Closing: The Company completed the acquisition of Dare Bioscience Operations, Inc. as outlined in the definitive proxy statement filed on June 19, 2017.
- Corporate Identity: The Company officially changed its name from Cerulean Pharma Inc. to Dare Bioscience, Inc.
- Capital Structure: A reverse stock split was executed in conjunction with the transaction closing.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the standard disclosures associated with the transaction. The primary focus is the confirmation of the completed merger and name change.
Key Facts for Investor Verification
- Verify the terms of the stock purchase agreement and the exchange ratio used in the Dare Transaction.
- Confirm the effective date and ratio of the reverse stock split.
- Review the attached press releases (Exhibits 99.1 and 99.2) for details on the combined entity's strategic direction.
- Check subsequent filings for the first consolidated financial statements reflecting the new corporate structure.